No, Breo and Breztri are NOT the same medication
Breo and Breztri are completely different inhaled medications with distinct drug combinations and different approved indications. While both are used for chronic lung disease, they contain different active ingredients and belong to different therapeutic classes.
Key Differences
Drug Composition
Breo (Breo Ellipta):
- Contains: Fluticasone furoate (ICS) + Vilanterol (LABA)
- Two-drug combination
- Once-daily dosing
Breztri (Breztri Aerosphere):
- Contains: Budesonide (ICS) + Glycopyrrolate (LAMA) + Formoterol (LABA) 1
- Three-drug "triple therapy" combination
- Twice-daily dosing
- Delivered via pressurized metered-dose inhaler using co-suspension delivery technology 2
Critical Distinction: The LAMA Component
The most important difference is that Breztri contains glycopyrrolate, a long-acting muscarinic antagonist (anticholinergic), which Breo does not have 1. This makes Breztri a triple therapy (ICS/LAMA/LABA) versus Breo's dual therapy (ICS/LABA).
Glycopyrrolate works by inhibiting M3 receptors in airway smooth muscle, providing additional bronchodilation through a different mechanism than the LABA component 1. This anticholinergic component is crucial for patients requiring more intensive COPD management.
Different Corticosteroids and LABAs
- Corticosteroids differ: Fluticasone (in Breo) versus budesonide (in Breztri)
- LABAs differ: Vilanterol (in Breo) versus formoterol (in Breztri)
- Formoterol has a more rapid onset of action compared to other LABAs, providing faster bronchodilation 1
Clinical Implications
When Breztri is Appropriate
Breztri is specifically indicated for COPD patients requiring triple therapy - those whose disease remains inadequately controlled on dual ICS/LABA or LAMA/LABA therapy 2. In pivotal trials, Breztri demonstrated:
- Reduced moderate/severe COPD exacerbation rates
- Improved lung function beyond dual therapy
- Reduced all-cause mortality risk
- Improvements in dyspnea, rescue medication use, and quality of life 2
When Breo is Appropriate
Breo is used for patients who need dual therapy (ICS/LABA) but don't yet require the additional anticholinergic component. This is typically an earlier step in COPD management or for asthma patients requiring combination therapy.
Common Pitfall to Avoid
Do not assume these medications are interchangeable simply because both contain an ICS and LABA. The addition of the LAMA component in Breztri represents a significant therapeutic escalation. Switching from Breo to Breztri (or vice versa) requires clinical reassessment of disease severity and treatment needs, not just a simple substitution.
The presence of three active ingredients in Breztri versus two in Breo fundamentally changes the pharmacologic approach to airway disease management, providing broader bronchodilation and anti-inflammatory coverage through multiple complementary mechanisms 1.